- Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions - http://eyedocnews.com -

Study on Using ILARIS® to Treat Proliferative Diabetic Retinopathy

Posted By Dr. Ari Weitzner On May 15, 2012 @ 12:56 pm In Clinical Trials,Diabetes,Research,Retina | Comments Disabled

The Department of Ophthalmology at Triemli Hospital in Zurich is recruiting recipients for a study evaluating the efficacy and safety of Canakinumab (ILARIS®) to treat proliferative diabetic retinopathy secondary to type 1 and 2 diabetes.

Ten subjects will be enrolled to receive 150 mg Canakinumab (ILARIS®) by subcutaneous injection. Beginning on day 0, each subject will receive a subcutaneous injection of study drug every 8 weeks for 16 weeks, a total of 3 injections. All subjects will undergo regular follow-up assessments every 8 weeks through 24 weeks. Fluorescein angiography (FA) will be repeated every 8 weeks. The primary outcome being sought is the regression of retinal neovascularizations by week 24.

Key secondary outcomes sought include regression of diabetic macular edema, and change in best-corrected visual acuity.

Click here [1] to learn more about this study.


Article printed from Breaking News Related to Macular Degeneration, Cataract, Glaucoma, Corneal Disease and Other Eye Conditions: http://eyedocnews.com

URL to article: http://eyedocnews.com/006659-study-on-using-ilaris-to-treat-proliferative-diabetic-retinopathy/

URLs in this post:

[1] Click here: http://www.clinicaltrials.gov/ct2/show/NCT01589029

Copyright © 2008 Eye Doc Talk. All rights reserved.